Clinical Trial Update: Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a capecitabine-temozolomide combination versus Lutetium-177 dotatate in patients with advanced pancreatic neuroendocrine tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Carcinoma
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)
• Temodar (Temozolomide)
• Xeloda (capecitabine)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING